Spyre Therapeutics (NASDAQ:SYRE) Stock

Spyre Therapeutics

Aeglea BioTherapeutics

Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

APGE

AVAV

DAVE

KRYS

NYCB

REAL

RSKD

SRRK

SYRE

U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday.

NIO Reports Upbeat Earnings, Joins Dave, V2X, Riskified And Other Big Stocks Moving Higher On Tuesday

Spyre Therapeutics Inc

Rosenblatt analyst Kevin Cassidy maintains CEVA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEVA#NASDAQ">CEVA</a>) with a Buy and maintains $35 price target.

Price Target

Analyst Ratings

CEVA

Rosenblatt Maintains Buy on CEVA, Maintains $35 Price Target

WIIM

SERA

Sera Prognostics shares are trading lower after the company announced a $50 million public offering.

ON Semiconductor Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) posted downbeat quarterly <a href="https://www.benzinga.com/quote/on/earnings">results on Monday</a>.
The company reported a fiscal fourth-quarter 2024 revenue decline of 15% year-on-year to $1.72 billion, missing the analyst consensus estimate of $1.76 billion. The adjusted EPS of 95 cents missed the analyst consensus estimate of 97 cents.
&#8220;As we continue to navigate this market downturn, our actions over the last four years have proven we are a structurally different company that is well-equipped to navigate prolonged volatility,&#8221; said Hassane El-Khoury, president and CEO, onsemi. &#8220;While 2025 remains uncertain, we remain committed to our long-term strategy. We will maintain our financial discipline, streamline our operations and continue to deliver high-value, differentiated intelligent power and sensing solutions that position onsemi to emerge even stronger.&#8221;
ON Semiconductor expects first-quarter adjusted revenue of $1.35 billion—$1.45 billion, below the consensus of $1.69 billion. The company expects adjusted EPS of $0.45–$0.55 below the consensus of $0.89 and an adjusted gross margin of 39.0%-41.0%.
ON Semiconductor shares fell 8.2% to close at $47.04 on Monday.
These analysts made changes to their price targets on ON Semiconductor following earnings announcement.
<ul>
<li>Citigroup analyst Christopher Danely maintained ON Semiconductor with a Neutral and lowered the price target from $77 to $52.</li>
<li>Morgan Stanley analyst Joseph Moore maintained the stock with an Underweight and lowered the price target from $52 to $44.</li>
<li>JP Morgan analyst Harlan Sur maintained ON Semiconductor with a Neutral and lowered the price target from $88 to $60.</li>
<li>Mizuho analyst Vijay Rakesh maintained the stock with an Outperform and lowered the price target from $85 to $71.</li>
<li>Needham analyst Quinn Bolton maintained ON Semiconductor with a Buy and cut the price target from $66 to $57.</li>
<li>Rosenblatt analyst Kevin Cassidy maintained the stock with a Neutral and slashed the price target from $75 to $49.</li>
</ul>
Considering buying ON stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11083552/image-94-1024x576.png" alt="" class="wp-image-776600" style="width:496px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11083552/image-94-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11083552/image-94-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11083552/image-94-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11083552/image-94.png 1191w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/25/02/43592071/top-3-tech-stocks-that-may-jump-this-month">Top 3 Tech Stocks That May Jump This Month</a></li>
</ul>

These Analysts Slash Their Forecasts On ON Semiconductor After Downbeat Results

Company Sharpens Focus on Data Center and AI Investment Opportunities

Management

DOMH

Donald Trump Jr. And Eric Trump Join Dominari Holdings Advisory Board

TANH

Tantech Holdings shares are trading lower after the company announced approval for a 1-for-40 reverse stock split in order to comply with Nasdaq listing standards.

Offerings

Dominari Holdings Announces $13.5M Registered Direct And Private Placement At $3.47/Share And Accompanying Warrants

AMPG

AmpliTech Group Announces $2.1M In New Purchase Orders , Set For Delivery In Fiscal Year 2025

XRAY

Dentsply Sirona shares are trading higher after the company initiated a review of strategic alternatives for its Wellspect Healthcare business.

OGEN

Oragenics shares are trading higher after the company partnered with BRAINBox Solutions to develop the first intranasal therapy for mild traumatic brain injury.

AIM ImmunoTech shares are trading higher after the company announced it will not proceed with an offering under its Form S-1 registration statement until after filing its annual report.

<ul>
<li>CircleDNA powers blockchain-based identity verification with Humanity Protocol, valued at US $1.1bn after latest fundraise</li>
<li>Prenetics invests $1.5M in Bitcoin, Solana and H tokens, supported by strong balance sheet</li>
<li>Prenetics advances Decentralized Science (DeSci) with AI-driven early cancer detection, backed by $30M investment from Tencent</li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Prenetics Partners With Humanity Protocol And Launches Crypto Strategic Reserve; Prenetics Invests $1.5M In Bitcoin, Solana And H Tokens

Guidance

NNN REIT Expects 2025 Core FFO Per Share Guidance Of $3.33 - $3.38, Est $3.37

Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) is rewriting the record books. The stock notched its 16th straight winning session on Monday, the longest streak among <a href="https://www.benzinga.com/topic/magnificent-seven">the Magnificent Seven</a>. 
At $717.40, it's knocking on the door of its all-time high of $725.01—and Wall Street can't seem to get enough.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="631" height="486" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11072240/Screenshot-2025-02-11-at-5.52.22-PM.png" alt="" class="wp-image-776445" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11072240/Screenshot-2025-02-11-at-5.52.22-PM.png 631w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11072240/Screenshot-2025-02-11-at-5.52.22-PM-300x231.png 300w" sizes="(max-width: 631px) 100vw, 631px" /></figure>
<h2 class="wp-block-heading">Resilient to AI Jitters, Thriving on AI Growth</h2>
Even as AI-driven sell-offs rattled the tech sector — like when Chinese startup DeepSeek blindsided Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) — Meta held its ground.
Unlike chipmakers, who live and die by AI hardware demand, Meta has AI-powered Advantage+ shopping ads, which grew 70% last quarter and hit a $20 billion annual run rate. 
Read Also: <a href="https://www.benzinga.com/25/02/43613038/openais-chatgpt-surpasses-elon-musks-x-and-yahoo-to-rank-sixth-most-visited-website-globally-sam-altman-says-still-a-long-way-to-go-to-run-down-google">OpenAI&#8217;s ChatGPT Surpasses Elon Musk&#8217;s X To Rank Sixth Most-Visited Website Globally — Sam Altman Says, &#8216;Still A Long Way To Go To Run Down Google&#8217;</a>
<h2 class="wp-block-heading">Zuckerberg's Performance Purge</h2>
Despite the stock's relentless climb, not all is smooth sailing inside Menlo Park. Meta is <a href="https://www.hindustantimes.com/business/meta-to-start-laying-off-3-000-employees-today-as-company-shifts-focus-to-ai-hiring-101739241876179.html">axing</a> 3,000 employees this week in a performance-driven purge. CEO Mark Zuckerberg has warned that 2024 and 2025 will be "challenging years" as the company doubles down on AI and metaverse bets.
Zuckerberg elaborated on comedian Joe Rogan&#8216;s <a href="https://www.youtube.com/watch?v=7k1ehaE0bdU">podcast</a>, saying he planned to replace mid-level engineers at his company with AI systems.
Wall Street doesn't seem to care. Unlike past layoffs that spooked markets, investors see this as a leaner, meaner Meta primed for efficiency and growth.
<h2 class="wp-block-heading">Meta Stock Chart Screams ‘Bullish'</h2>
With Meta trading above its eight, 20, 50 and 200-day simple moving averages, the trend is undeniably bullish. Even the MACD (moving average convergence/divergence) indicator at 28.12 and RSI (relative strength index) at 80.22 suggest strong momentum—though an RSI that high could mean it's getting overheated.
<h2 class="wp-block-heading">What's Next?</h2>
With Nvidia's earnings still on deck, the AI trade could see fresh volatility. 
But for now, Meta remains the only Mag 7 stock that rallied after earnings, and bulls aren't blinking. The question is: can this streak keep running, or is a breather overdue?
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43591253/amazons-ai-bet-is-big-but-will-investors-stick-around-for-the-lumps">Amazon&#8217;s AI Bet Is Big, But Will Investors Stick Around For The &#8216;Lumps&#8217;?</a></li>
</ul>
Image: Shutterstock

Long Ideas

Tech

NVDA

Meta Outperforms Magnificent 7 As 16-Day Streak Puts Bulls In Control

Dentsply Sirona Initiates Review Of Strategic Alternatives For Its Wellspect Healthcare Business

IMNM

Aro Biotherapeutics Appoints President And CEO As Board Chair; Appoints Purnanand Sarma As CEO

An investor group led by Elon Musk has proposed a <a href="https://www.benzinga.com/25/02/43609104/elon-musk-co-founded-openai-now-hes-bidding-974b-to-take-back-the-company">$97.4 billion bid to take</a> control of OpenAI, a move that OpenAI&#8217;s CEO, Sam Altman, thinks may be an attempt to &#8220;slow down a competitor.&#8221;
What Happened: Altman cast doubt on Musk&#8217;s true intentions behind the bid. He dismissed the notion that Musk was genuinely interested in acquiring OpenAI, stating, &#8220;Not particularly&#8221;, in an interview with&nbsp;<a href="https://www.cnbc.com/2025/02/11/musks-97point4-billion-for-openai-aims-to-slow-down-a-competitor-sam-altman-says.html">CNBC</a>&nbsp;on Tuesday
Altman believes that Musk&#8217;s bid could be a strategic maneuver to hinder a competitor and gain an advantage with his own AI company, xAI. The $97.4 billion offer, confirmed by CNBC on Monday,&nbsp;is for the nonprofit that&nbsp;supervises the artificial intelligence startup responsible for ChatGPT.
Musk&#8217;s legal representative, Marc Toberoff, confirmed that the offer was submitted on Monday, adding, &#8220;It&#8217;s time for OpenAI to return to the open-source, safety-focused force for good it once was.&#8221;
SEE ALSO: <a href="https://www.benzinga.com/markets/asia/25/02/43613949/tesla-supplier-catl-eyes-5-billion-hong-kong-listing-amid-us-sanctions-market-revival-report">Tesla Supplier CATL Eyes $5 Billion Hong Kong Listing Amid US Sanctions, Market Revival: Report</a>
Why It Matters: Elon Musk, who co-founded OpenAI, had previously departed from the company in 2018 over disagreements about its direction. His current bid comes as OpenAI transitions to a for-profit structure, a move Musk has legally challenged.
Founder of Telluride Legal Strategies, Rob Rosenberg indicated that Musk&#8217;s actions might create challenges for OpenAI as it seeks to shift away from its non-profit status, as per Bloomberg. Musk and Altman have been engaged in a prolonged dispute. In August, Musk also filed a lawsuit against OpenAI calling its partnership with Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) a &#8216;monopoly&#8217; aiming to eliminate competitors. 
OpenAI&#8217;s AI-powered chatbot, ChatGPT, has recently&nbsp;<a href="https://www.benzinga.com/25/02/43613038/openais-chatgpt-surpasses-elon-musks-x-and-yahoo-to-rank-sixth-most-visited-website-globally-sam-altman-says-still-a-long-way-to-go-to-run-down-google">surpassed</a>&nbsp;Musk&#8217;s X in web traffic, ranking as the sixth most-visited website globally in January 2025. This could potentially be a factor in Musk&#8217;s bid for control of the company. 
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/markets/equities/25/02/43591228/sam-altmans-openai-set-to-finalize-in-house-ai-chip-reducing-dependence-on-nvidia-report">Sam Altman&#8217;s OpenAI Set To Finalize In-House AI Chip, Reducing Dependence On Nvidia: Report</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

MSFT

Sam Altman Says Elon Musk's $97B Bid For OpenAI Is A Move To 'Slow Down A Competitor'

Abbott Laboratories's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) short percent of float has risen 4.82% since its last report. The company recently reported that it has 14.97 million shares sold short, which is 0.87% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.07 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Abbott Laboratories Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739280759_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Abbott Laboratories has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Abbott Laboratories's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Abbott Laboratories's peer group average for short interest as a percentage of float is 3.78%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Abbott Laboratories's Recent Short Interest

Ares Management's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARES#NYSE">ARES</a>) short percent of float has fallen 7.21% since its last report. The company recently reported that it has 3.77 million shares sold short, which is 2.06% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.72 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ares Management Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739280754_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ares Management has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Ares Management's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ares Management's peer group average for short interest as a percentage of float is 3.31%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

ARES

How Is The Market Feeling About Ares Management?

Ingersoll Rand's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IR#NYSE">IR</a>) short percent of float has risen 6.91% since its last report. The company recently reported that it has 9.38 million shares sold short, which is 2.63% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.79 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ingersoll Rand Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739280749_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ingersoll Rand has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Ingersoll Rand's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ingersoll Rand's peer group average for short interest as a percentage of float is 2.92%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Ingersoll Rand's Recent Short Interest

Rosenblatt analyst Catharine Trebnick maintains Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Buy and raises the price target from $212.5 to $235.

PANW

Rosenblatt Maintains Buy on Palo Alto Networks, Raises Price Target to $235

Press Releases

Spyre Therapeutics Added to the Nasdaq Biotechnology Index

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE

Comments

Spyre Therapeutics

Loading...

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga